ENTITY
Pathios Secures $25M in Funding from BMS to Advance GPR65 Checkpoint Inhibitor Development
Pathios, Bristol-Myers Squibb (BMS), funding, GPR65, checkpoint inhibitor, cancer immunotherapy, drug development, biotechnology, investment.
Charles River Launches Initiative for Animal Testing Alternatives
Charles River, Animal Testing Alternatives, Program Launch, Non-Animal Testing, Drug Development
MedinCell and AbbVie Collaborate on Long-Acting Injectable Development with a Potential Value of $1.9 Billion
MedinCell, AbbVie, Long-acting injectable, Development pact, $1.9 billion
Fujifilm Diosynth’s Restructuring Plan May Leave 240 Employees Jobless
Fujifilm Diosynth, CDMO (Contract Development and Manufacturing Organization), Restructuring plan, Potential job loss, 240 staffers
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
Sage Therapeutics’ Dalzanemdor Outcomes Amid Parkinson’s Miss
Sage Therapeutics Dalzanemdor Parkinson
Sanofi Downsizes IGM Antibody Deal, Reduces Oncology Focus
Sanofi, IGM Biosciences, antibody deal, oncology, downsizing, partnership
Eli Lilly’s Zepbound Shows Promising Results in Reducing Sleep Apnea Severity in Pivotal Trials
Eli Lilly, Zepbound, Sleep Apnea, Obstructive Sleep Apnea (OSA), Pivotal Trials, Obesity, GLP-1 Receptor Agonist, Tirzepatide, CPAP, Weight Loss
Detailed PHOENIX Study Reveals Relyvrio’s Failure in ALS Treatment
Relyvrio, PHOENIX study, Amyotrophic Lateral Sclerosis (ALS), Trial failure, Amylyx Pharmaceuticals
AbbVie Secures Deal with Medincell for Long-Acting Injectable Platform, Valued up to $1.9 Billion
AbbVie, Medincell, Long-acting injectable platform, Biotechnology, Deal, $1.9 billion